Key result
Luteolin significantly inhibited pseudorabies virus in vitro with an IC50 of 26.24 μM and improved the survival rate of mice after lethal challenge.
Why the study?
Increasing numbers of PRV variants have emerged in China despite available vaccines, highlighting the need to identify effective antiviral agents against PRV.
Answers are grounded in this paper and cite their sources.
Luteolin inhibits PRV in vitro; leaves open therapeutic potential pending in vivo and clinical validation.
Pseudorabies virus (PRV) can cause acute swine disease leading to economic losses worldwide and is a potential causative agent of viral encephalitis in humans. Although effective vaccines are available, an increasing number of variants have emerged in China, and identifying effective antiviral agents against PRV to prevent latent infection is essential. In this study, we assessed the antiviral activity of luteolin against PRV in vitro and in vivo. Luteolin was found to significantly inhibit PRV at a noncytotoxic concentration (70 μM), with an IC50 of 26.24 μM and a selectivity index of 5.64. Luteolin inhibited the virus at the replication stage and decreased the expression of viral mRNA and gB protein. Luteolin reduced the apoptosis of PRV-infected cells, improved the survival rate of mice after lethal challenge, reduced the viral loads in the liver, kidney, heart, lung, and brain, reduced brain lesions, and slowed inflammation and oxidation reactions. Our results showed that luteolin has promise as a new alternative antiviral drug for PRV infection.
No takes yet. Share an insight, caveat, or question.
Men et al. (2023) studied Pseudorabies virus (PRV) infection. Luteolin was evaluated on Antiviral activity (IC50). Luteolin significantly inhibited pseudorabies virus in vitro with an IC50 of 26.24 μM and improved the survival rate of mice after lethal challenge.
Synapse has enriched 10 related papers. Consider them for comparative context: